Based on the current information, breast, gastric, hepatocellular and esophageal carcinoma might qualify for ICI HLA-G therapy, while cervical, colorectal, lung, oral, ovarian and pancreatic carcinoma still does not. Here, HLA-G is linked to exocrine pancreatic carcinoma.